Friday, 17 Nov 2017

You are here

NSAID and Opioid Adverse Event Reports from MedWatch

One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids. This report from the MedWatch system shows that 20% of reports were associated with death, with near equal contribution by NSAIDs, opioids and combination (NSAIDs plus opioids).

With growing concern over the safety of these agents, investigators reviewed data collected between 2015 and 2016 from the FDA’s Adverse Events Reporting System (FAERS or MedWatch) to analyze the comparative frequencies and demographics of those reporting painkiller-related AEs.

Over 2 million adverse event (AE) reports were submitted to FAERS during this period and nearly 3% (64,354) were were associated with painkillers.

Opioid-associated AEs were more likely to be from males or younger patients (mean age 47.6 years). The

The most frequent AEs were from drug ineffectiveness, administration issues, abuse, and overdose associated with NSAID and opioid use.

Death was reported in 20.0% of the reports, and serious adverse reactions (SAE), including death, were reported in two-thirds.

Death and SAEs highest among patients using opioids or combinations users.

Given the great focus on opioid hazards, these data suggest that NSAIDs and combination painkillers may be as hazardous as opioids when looking at FAERS reports.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

J&J Hit with a $247 Million Verdict over Metal-on-Metal Hip Replacements

Reuters reports that a federal jury has ordered Johnson & Johnson and its DePuy Orthopaedics division to pay $247 million settlment to six patients who suffered from its defective Pinnacle, metal-on-metal, hip implants. in the US. J&J says it will  appeal this decision.

These implants were associated with tissue necrosis, bone erosion and other injuries due to implant design.

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source https://buff.ly/2z04f9h)

Cardiovascular Events: Allopurinol vs. Febuxostat

In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.

Low-dose Bactrim Safe with Methotrexate in AAV

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

CRIB Study Shows No Transplacental Transfer of Certolizumab

Mariette and colleagues have reported on the prospective pharmacokinetic study of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants at the time of birith. They found no to minimal CZP in infant blood at the time of delivery, suggesting a lack of in utero fetal exposure during the third trimester.